On August 27, 2024 Privo Technologies reported the receipt of $4.5 million in funding from the National Cancer Institute to support our pivotal Phase 3 clinical trial for a groundbreaking nanotechnology-based treatment targeting carcinoma in situ of the oral cavity (Stage 0 oral cancer) (Press release, Privo Technologies, AUG 27, 2024, View Source;utm_medium=rss&utm_campaign=privo-technologies-receives-4-5m-funding-from-national-cancer-institute-for-phase-3-clinical-trial-of-innovative-oral-cancer-treatment [SID1234646122]). This funding is a critical milestone in our journey toward seeking regulatory approval for PRV111, our innovative treatment designed to revolutionize the standard of care for patients with rare, orphan diseases.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The continued support from the National Cancer Institute not only affirms the potential of our technology but also accelerates our ability to move forward in the regulatory process. With these resources, Privo can conduct the necessary research and clinical studies to demonstrate the safety and efficacy of our treatment, bringing us closer to delivering new therapies to patients who have limited options. This funding is instrumental in advancing our mission to make a meaningful impact on the lives of those battling rare forms of cancer, as we strive to bring this promising treatment to market.